P
Piero Verro
Researcher at University of California, Davis
Publications - 38
Citations - 3193
Piero Verro is an academic researcher from University of California, Davis. The author has contributed to research in topics: Stroke & Brain ischemia. The author has an hindex of 24, co-authored 38 publications receiving 3018 citations. Previous affiliations of Piero Verro include Seton Hall University & Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study
TL;DR: In this article, the authors evaluated the safety profile and adverse events in patients treated with intravenous tissue-type plasminogen activator (tPA) for acute stroke in clinical practice.
Journal ArticleDOI
Predictors of Fatal Brain Edema in Massive Hemispheric Ischemic Stroke
Scott E. Kasner,Andrew M. Demchuk,Andrew M. Demchuk,Jörg Berrouschot,Erich Schmutzhard,Lutz Harms,Piero Verro,Julio A. Chalela,Rekha Abbur,Harold McGrade,Ioannis Christou,Derk W. Krieger +11 more
TL;DR: Among patients with large MCA infarctions, an increased risk of fatal brain edema is associated with history of hypertension or heart failure, increased baseline white blood cell count, major early CT hypodensity involving >50% of the MCA territory, and involvement of additional vascular territories.
Journal ArticleDOI
Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study
Yang Tang,Huichun Xu,Xin Li Du,Lisa Lit,Wynn Walker,Aigang Lu,Ruiqiong Ran,Jeffrey P. Gregg,Melinda Reilly,Art Pancioli,Jane Khoury,Laura Sauerbeck,Janice Carrozzella,Judith Spilker,Joseph F. Clark,Kenneth R. Wagner,Edward C. Jauch,Dongwoo J Chang,Piero Verro,Joseph P. Broderick,Frank R. Sharp +20 more
TL;DR: Int insights into the inflammatory responses after stroke in humans are provided, and should be helpful in diagnosis, understanding etiology and pathogenesis, and guiding acute treatment and development of new treatments for stroke.
Journal ArticleDOI
Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
David Tanne,David Tanne,Vernice E. Bates,Piero Verro,Scott E. Kasner,Jeffrey R. Binder,Suresh C. Patel,H. H. Mansbach,Sheila Daley,Lonni Schultz,P. N. Karanjia,Phillip A. Scott,J. M. Dayno,K. Vereczkey-Porter,Curtis G. Benesch,Diane S. Book,William M. Coplin,Douglas A. Dulli,Steven R. Levine +18 more
TL;DR: Initial clinical experience with IV tissue plasminogen activator treatment of acute ischemic stroke in a standardized retrospective survey of hospitals with experienced acute stroke treatment systems is assessed, suggesting that strict adherence to protocol guidelines is prudent.
Journal ArticleDOI
Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Henrik Sillesen,Gregory W. Albers,Irfan Altafullah,Oscar Benavente,Diane S. Book,Joseph P. Broderick,Christopher Calder,Alfred Callahan,Walter Carlini,Seemant Chaturvedi,Thomas Chippendale,Wayne M. Clark,Greg Collins,Bruce M. Coull,Patricia H. Davis,Thomas Devlin,Arthur Dick,Lucy Younger Dirr-Ledbetter,George Dooneief,R. Scott Duff,Nordeli Estronza,Alejandro M. Forteza,Michael Frankel,James L. Frey,Gary Friday,Jerome Goldstein,Steven Goldstein,Gleen Graham,Wayne Harper,Jonathan Harris,Barry Hendin,David C. Hess,Richard Hinton,Joshua Hollander,Chung Y. Hsu,Richard L. Hughes,Scott E. Kasner,Thomas A. Kent,Lance Kim,Howard S. Kirshner,Marian P. LaMonte,Kenneth Levin,Richard B. Libman,Paul McDowell,Francis E. McGee,Brett C. Meyer,Alireza Minagar,Frederick Munschauer,Richard Munson,Marshall Nash,Sean C. Orr,Gerald Ratinov,Virgilio D. Salanga,Souvik Sen,Scott Silliman,Richard Singer,Don Smith,Herman Sullivan,David E. Thaler,Gretchen E. Tietjen,Michael Tuchman,David Uskavitch,Piero Verro,Ralph Vicari,Richard Weinstein,J. L. Wilterdink,Richard M. Zweifler,Michael Beaudry,Robert Côté,Keith Hoyte,Louise Hélène Lebrun,John W. Norris,Daniel Selchen,Ashfaq Shuaib,Denis Simard,David Spence,Philip Teal,Michael Winger,Reinhold Schmidt,Bruno Pramsohler,Christoph Schmidauer,Markku Kaste,Juhani Sivenius,Anna Wagner,Andreas Terént,Pierre Amarenco,Loic Milandre,François Chollet,Thomas de Broucker,Thierry Moulin,Etienne Roullet,Didier Leys,Marie Hélène Mahagne,Michael G. Hennerici,Wolf-Dieter Heiss,Otto Busse,Roman L. Haberl,Lutz Harms,C. Diener,Gerhard F. Hamann,E. Bemd Ringelstein,Nicola Canal,Antonio Capurso,Angelo Mamoli,Lodovico Frattola,Carlo Gandolfo,Umberto Senin,Michele Zito,Keyser de Keyser,Peter J. Koudstaal,J. A. Haas,G. de Jong,Julien Bogousslavsky,Heinrich Mattie,Ralf W. Baumgartner,Ronald S. MacWalter,Roelfe Dijkhuizen,Enefioke Ben Ekpo,Philip M.W. Bath,Kennedy R. Lees,José M. Ferro,Luís Cunha,Antonio Dávalos,Ángel Chamorro,Alvarez Sabin,Dolores Jimenez,Jose Ramon Gonzalez,Aida Lago,Jose Antonio Egido,Jose Vivancos,Matias Guiu,Geoffrey Dorman,Stephen M. Davis,David Gilles,Judy Frayne,Denis Crimmins,Simon Dimmit,Gagrath Pradeep Singh,Russell S. Scott,Neil E Anderson,J. Carr,A. K. Kruger,J. Gardiner +142 more
TL;DR: The SPARCL Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effect of statin treatment in secondary stroke prevention.